Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology | Evaluate
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Accord entre Pierre Fabre et Puma Biotechnology
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
THE FACES OF BREAST CANCER
Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Fight against cancer : our therapeutic responses | Pierre Fabre
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Fight against cancer : our therapeutic responses | Pierre Fabre
